As 2025 draws to a close, it is evident that the industry has not pursued radical transforma...
As 2025 draws to a close, it is evident that the industry has not pursued radical transforma...
Antibody-drug conjugates have arisen as a groundbreaking class of targeted cancer therapies,...
The ChallengeA small molecule CDMO faced over a 70% turnover rate, struggled to meet product...
We filled 35+ critical HEOR, Market Access, and RWE roles, enabling global product commercia...